Webinar: Novel flow cytometry ACE-2 blocking assay 12SHARES Share via Pinterest Reddit Buffer Xing WhatsApp Flipboard Posted: 8 January 2021 | Bio-Techne | No comments yet This webinar from Bio-Techne demonstrates how to use a novel in vitro flow cytometry-based assay to monitor SARS-CoV-2 binding to ACE-2. ACE-2 is a widely expressed receptor that is utilized by SARS-CoV-2 to enter cells. Antibody or small molecule blockade of this interaction could be a viable COVID-19 therapeutic option; however, this research is hampered by biosafety considerations. We developed an in vitro flow cytometry assay for evaluating the effectiveness of antibodies or small molecules to block SARS-CoV-2 binding. This webinar from Bio-Techne demonstrates how to use this assay to monitor SARS-CoV-2/ACE-2 interactions. To watch this video in full, please complete the form below: First Name * Surname * Job Title * Organisation * Town/City * Country * —Please choose an option—AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCook IslandsCosta RicaCote D'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFaeroe IslandsFalkland IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadaloupeGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHeard and McDonald IslandsVatican CityHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaKosovaKuwaitKyrgyz RepublicLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian TerritoryPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandPolandPortugalPuerto RicoQatarReunionRomaniaRussiaRwandaSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbia and MontenegroSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSpainSri LankaSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudanSurinameSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUnited States of AmericaUruguayUS Virgin IslandsUzbekistanVanuatuVenezuelaVietnamWallis and Futuna IslandsWestern SaharaYemenZambiaZimbabwe Email * Telephone This specialist content is provided to you free-of-charge thanks to the kind support of Bio-Techne I agree to receive relevant marketing communications regarding products, industry news, literature, and events from Bio-Techne and its brands (ProteinSimple, R&D Systems, Novus Biologicals, Tocris Bioscience and Advanced Cell Diagnostics). I understand that I can change my preferences at any time. I further understand that any data provided to Bio-Techne and its brands will be stored, used, and deleted consistent with Bio-Techne's Privacy Notice *—Please choose an option—YesNo By clicking submit you confirm that you accept our terms and conditions and privacy policy. Related topicsAnalytical Techniques, Antibodies, Assays, Biopharmaceuticals, Immunology Related organisationsBio-Techne
webinar Advancing ADC Development: End-to-End Solutions from Design to Characterisation By Eurofins Discovery
article Gene silencing: a step forward for rare disease therapy By Dr Dan Williams (Co-founder and CEO of SynaptixBio)